New scan could pinpoint best drug for tough breast cancers
NCT ID NCT06830382
Summary
This study is testing a new type of PET scan to see if it can better identify which patients with advanced breast cancer are likely to benefit from a specific targeted drug called T-DXd. The scan looks for a protein called HER2 on cancer cells. Researchers hope this more precise imaging will help match the right patients to the right treatment, potentially improving outcomes and reducing unnecessary side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Karolinska University hospital
RECRUITINGSolna, 17176, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.